{"id":"NCT00114127","sponsor":"Massachusetts General Hospital","briefTitle":"Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome","officialTitle":"Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2008-11","completion":"2010-07","firstPosted":"2005-06-14","resultsPosted":"2012-06-07","lastUpdate":"2014-06-10"},"enrollment":28,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta"]},{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine 60mg + Placebo for 18 Weeks","type":"PLACEBO_COMPARATOR"},{"label":"Duloxetine 120mg for 18 Weeks","type":"ACTIVE_COMPARATOR"},{"label":"Duloxetine 60mg/day for 6 Weeks","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.","primaryOutcome":{"measure":"Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale","timeFrame":"6 months","effectByArm":[{"arm":"Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)","deltaMin":67.9,"sd":7.6},{"arm":"Duloxetine 120mg/Day for 18 Weeks (Phase 2)","deltaMin":53.7,"sd":7.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.132"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mghanxiety.org"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":13},"commonTop":["Sedation and other side effects","Increased drinking"]}}